RECENT FUNDING
  1. Recent Funding
  2. Investors
  3. RA Capital Management
R

RA Capital Management portfolio

RA Capital Management has 44 portfolio companies on record at Recent Funding, with 19 investments in the last 12 months.

Type: Investor.
Portfolio on Recent Funding: 44.
Deals, last 12 months: 19.
Rounds led: 17 of 56.
Capital in their rounds: $6.58B.
Latest deal: Delix · Nov 9, 2026.
About this page

It led 17 of the 56 rounds it joined. Its most recent investment on record is Delix's funding round in November 2026, alongside OMX Ventures, Vestal Point Capital, Dolby Family Ventures and 6 others. By category, its portfolio leans toward Health and bio (42) and Manufacturing and industrial (4). It has co-invested with Janus Henderson Investors, Soleus Capital and Sofinnova Partners, most often Janus Henderson Investors (11 rounds).

What RA Capital Management invests in

RA Capital Management recent investments

How RA Capital Management invests

StageDealsCapital in rounds
Series B+ 38 68%$4.93B
Series A 17 30%$1.65B
round 1 2%undisclosed
YearDealsCapital in rounds
2019 1 2%$67M
2020 2 4%$178M
2021 9 16%$1B
2022 6 11%$450M
2023 4 7%$665M
2024 9 16%$1.07B
2025 8 14%$1.23B
2026 17 30%$1.91B

RA Capital Management portfolio companies

CompanyRound with RA Capital ManagementTotal raisedLatest raise
DDelix
Health and bio
roundundisclosedNov 9, 2026
round
AAlethio Therapeutics
Health and bio
Series A · $90M · lead$90MNov 5, 2026
Series A
SStar Therapeutics
Health and bio
Series B+ · $200M$415MOct 23, 2026
Series B+
OOptivolt
Climate and energy
Series A · $32M$40MOct 21, 2026
Series A
EEstuary Biotherapeutics
Health and bio
Series A · $103M · lead$103MOct 16, 2026
Series A
AAbcuro
Health and bio
Series B+ · $66M$463MAug 18, 2026
Series B+
LLifeMine Therapeutics
Health and bio
Series B+ · $188M$543MAug 6, 2026
Series B+
CCelea Therapeutics
Health and bio
Series A · $180M$180MJul 2, 2026
Series A
CContraline
Health and bio
Series B+ · $92.5M · lead$105.45MJun 2, 2026
Series B+
CCellCentric
Health and bio
Series B+ · $220M$340MMay 6, 2026
Series B+
PPinnacle Medicines
Health and bio
Series B+ · $89M$89MMar 26, 2026
Series B+
AAtavistik Bio
Health and bio
Series B+ · $40M · lead$220MMar 5, 2026
Series B+
NNexcure
Health and bio
Series A · $19M · lead$19MMar 5, 2026
Series A
AAngitia Bio
Health and bio
Series B+ · $130M$130MFeb 12, 2026
Series B+
CCorxel
Health and bio
Series B+ · $287M$287MJan 26, 2026
Series B+
KKinaset Therapeutics
Health and bio
Series B+ · $103M · lead$143MJan 9, 2026
Series B+
AAmbros Therapeutics
Health and bio
Series A · $125M · lead$125MDec 16, 2025
Series A
TTriana Bio
Health and bio
Series B+ · $120M$120MDec 3, 2025
Series B+
SSidera Bio
Health and bio
Series A · $109.99M$109.99MNov 4, 2025
Series A
RReframe Systems
Robotics and hardware
Series A · $20M$20MAug 26, 2025
Series A
VVerdiva Bio
Health and bio
Series A · $410M$410MJan 9, 2025
Series A
AAlpha-9 Oncology
Health and bio
Series B+ · $175M$175MOct 23, 2024
Series B+
IIDRx
Health and bio
Series B+ · $120M · lead$242MAug 8, 2024
Series B+
BBright Peak Therapeutics
Health and bio
Series B+ · $90M$125MAug 17, 2026
Series B+
AAltruBio
Health and bio
Series B+ · $225M$288MMay 21, 2024
Series B+
AAsher Bio
Health and bio
Series B+ · $55M · lead$218MApr 16, 2024
Series B+
TTorl Bio
Health and bio
Series B+ · $158M$412MOct 7, 2025
Series B+
FFrontier Medicines
Health and bio
Series B+ · $80M$235.5MAug 28, 2025
Series B+
MMMI
Health and bio
Series B+ · $110M$310MOct 8, 2026
Series B+
CClaris Bio
Health and bio
Series A · $57M$175MJul 28, 2026
Series B+
AAiolos Bio
Health and bio
Series A · $245M$245MNov 20, 2023
Series A
MMariana Oncology
Health and bio
Series B+ · $175M$175MSep 7, 2023
Series B+
CCurevo Vaccine
Health and bio
Series AundisclosedMar 18, 2025
Series B+
JJnana Therapeutics
Health and bio
Series B+ · $107M$207MNov 15, 2022
Series B+
AAnsa Biotechnologies
Health and bio
Series A · $68M$122.4MOct 1, 2025
Series B+
SSynthego
Health and bio
Series B+ · $200M$459MFeb 17, 2022
Series B+
TTasso
Health and bio
Series B+ · $100M · lead$123.1MDec 16, 2021
Series B+
TT-Knife
Health and bio
Series B+ · $110M$188MAug 2, 2021
Series B+
EElement Biosciences
Health and bio
Series B+ · $276M$823MJun 9, 2026
Series B+
SSynthekine
Health and bio
Series B+ · $108M$290MJan 6, 2023
Series B+
FForge Biologics
Health and bio
Series B+ · $120M · lead$250MSep 12, 2022
Series B+
AAdcytherix
Health and bio
backerundisclosedOct 16, 2025
Series A
WWindward Bio
Health and bio
backer$200MMay 5, 2026
round
EEnara Bio
Health and bio
backer$32.5MJun 2, 2026
Series B+

Most frequent co-investors

Similar investors

Investors whose portfolios on Recent Funding center on the same category (Health and bio).

How this is counted

Share is of the 56 rounds on Recent Funding that name RA Capital Management. Rounds with no announced date are left out of the year split, and "round" is a round whose stage is not on file.

Portfolio companies are the companies on Recent Funding with a round that lists RA Capital Management, which is a subset of its real portfolio. API: /api/v1/investors/ra-capital-management (get a free API key). More: the most active VC firms and new venture capital funds.

Top raises, every week

The week's top funded startups and market insights, in your inbox every Monday.

Unsubscribe anytime · privacy